Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7510677 | 0.95 | POLB (0.57) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL4687715 | 0.93 | LMNA (0.55) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL3953195 | 0.89 | POLB (0.49) | POLBSMN1; SMN2LMNAALDH1A1ATM | |
| SCHEMBL5542964 | 0.89 | SMN1; SMN2 (0.51) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL5535309 | 0.88 | LMNA (0.50) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL9405372 | 0.87 | POLB (0.73) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL1859157 | 0.83 | SMN1; SMN2 (0.69) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL3634052 | 0.83 | SMN1; SMN2 (0.69) | POLBSMN1; SMN2LMNAALDH1A1HRH2 | |
| SCHEMBL5543852 | 0.83 | SMN1; SMN2 (0.44) | POLBSMN1; SMN2LMNAALDH1A1ATM | |
| SCHEMBL74877 | 0.83 | TSHR (0.57) | POLBSMN1; SMN2LMNAALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027106-A2 | CGRP RECEPTOR ANTAGONISTS | Vertex Pharmaceuticals Incorporated (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | claimed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2027106-A2 | CGRP RECEPTOR ANTAGONISTS | Vertex Pharmaceuticals Incorporated (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1373234-B1 | UROKINASE INHIBITORS | WILEX AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | POLB 3988/4885SMN1; SMN2 2846/4885LMNA 1228/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | POLB 3203/4885SMN1; SMN2 4594/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.